Label: DAPSONE 8.5% / NIACINAMIDE 2% / SPIRONOLACTONE 5% gel

  • Category: HUMAN PRESCRIPTION DRUG LABEL

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated May 9, 2019

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

  • Directions for use

    de

  • Sincerus Florida, LLC. Adverse reactions

    dx

  • Active, inactive

    dw

  • NDC 72934-1064-2 DAPSONE USP 8.5% / NIACINAMIDE USP 2% / SPIRONOLACTONE USP 5%. Gel 30gm

    a

  • INGREDIENTS AND APPEARANCE
    DAPSONE 8.5% / NIACINAMIDE 2% / SPIRONOLACTONE 5% 
    dapsone 8.5% / niacinamide 2% / spironolactone 5% gel
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:72934-1064
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SPIRONOLACTONE (UNII: 27O7W4T232) (SPIRONOLACTONE - UNII:27O7W4T232) SPIRONOLACTONE5 g  in 100 g
    DAPSONE (UNII: 8W5C518302) (DAPSONE - UNII:8W5C518302) DAPSONE8.5 g  in 100 g
    NIACINAMIDE (UNII: 25X51I8RD4) (NIACINAMIDE - UNII:25X51I8RD4) NIACINAMIDE2 g  in 100 g
    Product Characteristics
    ColorwhiteScore    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:72934-1064-230 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product05/10/2019
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other05/10/2019
    Labeler - Sincerus Florida, LLC (080105003)
    Establishment
    NameAddressID/FEIBusiness Operations
    Sincerus Florida, LLC080105003manufacture(72934-1064)